Skip to main content
. 2018 Sep 28;286:10–19. doi: 10.1016/j.jconrel.2018.07.022

Fig. 4.

Fig. 4

In vivo pharmacokinetic profiles of bexarotene (BEX) and its prodrugs following intravenous administration in rats. BEX or prodrugs 2 and 25 were administered at doses equivalent to 2.5 mg/kg of BEX (mean ± SD, n = 3 each). Pharmacokinetic profile of BEX following intravenous administration of BEX has been previously reported by our group [33] and is shown here for comparison.